Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468240 | 0.90 | ITGA4 (0.54) | L3MBTL1PSMB1PSMB5PSMB2ITGA4 | |
| SCHEMBL2858587 | 0.87 | PSMB5 (0.51) | PSMB5ITGA4ITGB1ACKR3ITGB2 | |
| SCHEMBL5470915 | 0.83 | DHODH (0.44) | PSMB5NPC1RAB9AALDH1A1EPHX2 | |
| SCHEMBL2861620 | 0.83 | CTRB1 (0.51) | NPC1RAB9AALDH1A1EPHX2CTSL | |
| SCHEMBL5453401 | 0.82 | ACKR3 (0.46) | ACKR3ALDH1A1CTSL | |
| SCHEMBL2857888 | 0.81 | PSMB5 (0.52) | L3MBTL1PSMB5NPC1RAB9AACKR3 | |
| SCHEMBL2877086 | 0.78 | EPHX2 (0.61) | PSMB5NPC1RAB9AALDH1A1EPHX2 | |
| SCHEMBL2853485 | 0.78 | NPC1 (0.51) | NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL3281866 | 0.78 | EPHX2 (0.54) | NPC1RAB9AEPHX2MMEACE | |
| SCHEMBL2856055 | 0.77 | PTGES (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | L3MBTL1 1226/4885PSMB1 2125/4885PSMB5 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.